New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors.

Published in: American journal of hematology (2024)

Ruxolitinib in combination with navitoclax or pelabresib in myelofibrosis: activity in JAKi-naïve patients.

Keyphrases